Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
3749289
Reference Type
Journal Article
Title
Gender differences in pharmacokinetics and tissue distribution of 3 perfluoroalkyl and polyfluoroalkyl substances in rats
Author(s)
Kim, SJ; Heo, SH; Lee, DS; Hwang, IG; Lee, YB; Cho, HY
Year
2016
Is Peer Reviewed?
Yes
Journal
Food and Chemical Toxicology
ISSN:
0278-6915
EISSN:
1873-6351
Publisher
Elsevier
Volume
97
Issue
Elsevier
Page Numbers
243-255
Language
English
PMID
27637925
DOI
10.1016/j.fct.2016.09.017
Web of Science Id
WOS:000387627000026
URL
https://linkinghub.elsevier.com/retrieve/pii/S0278691516303325
Exit
Abstract
The aim of this study was to confirm and investigate the gender differences in pharmacokinetic (PK) characteristics and tissue distribution of 3 perfluoroalkyl and polyfluoroalkyl substances (PFASs) consisted of perfluorooctanoic acid (PFOA), perfluorooctanesulfonic acid (PFOS), and perfluorohexane sulfonic acid (PFHxS) in both male and female rats. For this study, a simultaneous determination method of the 3 PFASs in rat plasma and tissues was developed and validated using a UPLC-MS/MS system. The PK parameters after a single oral or intravenous administration of the 3 PFASs in both rats were calculated using WinNonlin(®) software. The mean half-life of the 3 PFASs in female and male rats was in the range of 0.15-0.19 and 1.6-1.8 days for PFOA, 23.5-24.8 and 26.4-28.7 days for PFOS, and 0.9-1.7 and 20.7-26.9 days for PFHxS, respectively. The 3 PFASs were highly distributed in the liver and kidney. These results suggest that there are gender differences in the PKs for PFOA and PFHxS in rats, whereas the PFOS represented no significant gender differences except the Kp value of liver. The validated simultaneous determination method of the 3 PFASs was also within the accepted criteria of the international guidance.
Keywords
PFOA; PFOS; PFHxS; Gender difference; Pharmacokinetics; Tissue distribution
Tags
PFAS
•
Additional PFAS (formerly XAgency)
•
Expanded PFAS SEM (formerly PFAS 430)
Litsearch: September 2019
PubMed
Web of Science
Not prioritized for screening
Perfluorooctane
Potassium perfluorooctanoate
Sodium perfluorooctanoate
•
^Per- and Polyfluoroalkyl Substances (PFAS)
PFOA (335-67-1) and PFOS (1763-23-1)
Literature Search – Adverse outcome pathway (2015-present)
Pubmed
WOS
PFHxS (355-46-4)
Literature search
Pubmed
WOS
•
PFAS 150
Literature Search Update December 2020
PubMed
WOS
Literature Search August 2019
PubMed
Web of Science
Not prioritized for screening
Ammonium perfluorooctanoate
Perfluorinated compounds
Perfluorohexanesulfonic acid
Perfluorooctane
Perfluorooctanesulfonic acid
Perfluorooctanoic acid
•
PFHxA
HAWC
•
PFHxS
Database searches
Pubmed
Toxline
WOS
Scopus
Inclusion
TiAb
Supplemental
Full Text
•
PFOA (335-67-1) and PFOS (1763-23-1)
Literature Search – Adverse outcome pathway (2015-present)
Pubmed
WOS
Screening Results
Toxicokinetic studies
ADME
Susceptible populations
Literature Search Update (2013-2019)
PubMed
WOS
•
PFOA and PFOS OW MCLG Approaches
Cited in White Papers
•
Yale PFAS Liver study
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity